Andrew Zhu
Medical Oncology · Boston, MANPI 1699741769
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $132,072 of the $207,403 with a category attached, or 63.7%. 18 manufacturers reported payments, led by Merck at 25.2% of the total. Reporting peaked in 2019 at $121,476 and has fallen 96.4% since, to $4,400 in 2022. Among medical oncology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $1355.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$52K
- Eli Lilly$24K
- F. Hoffmann-la Roche AG$24K
- Eisai CO., LTD.$19K
- Exelixis Inc.$16K
- Eisai Inc.$14K
- plus $58K from 12 others
Across 88 payments — averaging $5908.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$148K
- Eli Lilly$95K
- Merck$81K
- Agios Pharmaceuticals, Inc.$78K
- Novartis$51K
- F. Hoffmann-la Roche AG$35K
- plus $32K from 2 others
What the payments were for
- Consulting fees$132,07264%
- Speaking & faculty fees$32,44016%
- Travel & lodging$39,63719%
- Food & beverage$2,9431%
- Education$3120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 45 | $52,276 |
| Eli Lilly | 11 | $23,757 |
| F. Hoffmann-la Roche AG | 15 | $23,703 |
| Eisai CO., LTD. | 6 | $18,915 |
| Exelixis Inc. | 12 | $16,315 |
| Eisai Inc. | 14 | $14,258 |
| Bayer | 17 | $12,114 |
| Novocure Inc. | 2 | $7,800 |
| Sirtex Medical Inc | 4 | $7,083 |
| Sanofi US Services Inc. | 7 | $6,680 |
| Servier Pharmaceuticals LLC | 3 | $5,948 |
| Incyte Corporation | 6 | $5,423 |
| Beigene, Ltd. | 3 | $4,600 |
| Alnylam Pharmaceuticals Inc. | 1 | $4,096 |
| Boehringer Ingelheim International GmbH | 2 | $3,250 |
| Lilly USA, LLC | 1 | $875 |
| Genentech USA, Inc. | 2 | $255 |
| Agios Pharmaceuticals, Inc. | 2 | $54 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$207,403 in reported general payments places this provider in the 90th percentile of 308 medical oncology providers in Massachusetts.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.